Joshua Meeks

Priority review for TAR200 pretzel. A lot of uros are looking forward to giving this (as opposed to the other more hyped ones) jnj.com/media-center/p…

=> Please share! @PGrivasMDPhD @montypal @m_e_nielsen @SpiessPhilippe @FaltasLab @zklaassen_md @brian_rini @JoshMeeks @TiansterZhang @siadaneshmand @ERPlimackMD @shilpaonc @UroDocAsh @LauraBukavinaMD @sonpavde @urotoday @UrologyTimes

Deeply honored and truly grateful to @JedUro1 and @AndrewMcD_MD at @UABMedicine, @UABUrology, and @UABradonc for the incredible opportunity to serve as a special visiting professor in Birmingham discussing bladder preservation. Thank you for your generosity and hospitality!

@JoshMeeks provides an amazing overview of the significant data emerging in the BCG-unresponsive NMIBC space, focusing on the CIS cohorts. We also discuss the recent ODAC decision on UGN-102 for lower risk disease which was recently FDA approved. spotifycreators-web.app.link/e/szAiuFvyaUb

Great pleasure during #AUA25 to discuss with @JoshMeeks and @UroDocAsh the futur of BCG naive field The tremendous @IBCG_BladderCA plenary session was fantastic, really enjoyed our debate leaded by @LAUrology_NL urotoday.com/video-lectures…

Trials-in-Progress – Intravesical sacituzumab tirumotecan in participants with intermediate-risk #NMIBC: The phase 1/2 #TroFuse027 study. Presented by @JoshMeeks @NM_Urology. #ASCO25 written coverage by @RKSayyid @USC > bit.ly/4dMVaRk @ASCO

📢 #ASCO25 | NIAGARA ctDNA Analysis | MIBC pts on perioperative durvalumab: Baseline ctDNA+ in a subset linked to shorter EFS; early ctDNA clearance after D associated with improved DFS; persistent ctDNA post-surgery predicted relapse. Thomas Powles et al. Full abstract →…

#Niagara study at #ASCO25: Pre-surgery ctDNA is prognostic in perioperative MIBC. Being ctDNA– ≠ pCR, but if ctDNA+ → chances of pCR are close to zero. The real challenge: how should we define clinical CR to potentially avoid radical, mutilating surgery? Brilliant talk by…

NIAGARA ctDNA results presented at #ASCO25 🧬 ctDNA is prognostic ➡️ ctDNA negative patients have good DFS and ctDNA positive patient don’t do well Positive ctDNA pre-CX ➡️ negligible pCR ctDNA is making it’s way to clinical care 🩸🧬

👉 Dr. @tompowles1 shared the results of the phase 3 NIAGARA trial here at @ASCO. Read more about the study and its findings here: buff.ly/tJWHw65 #ASCO25

1/2 ctDNA data for durvalumab+NAC in MIBC from NIAGARA #ASCO25. 57%,22%,9% of pts are ctDNA +ve at baseline/post NAC/post surgery. Poor outcomes for cDNA+ve occur at each time point (HR 0.4,0.3,0.1 respectively). Chemo cleared the ctDNA in most pts & was ⬆️13% with durvalumab

One of my favorite things about spring is our annual visiting professor. Now named after Anthony J Schaeffer. This year we hosted James Eastham from @MSKCancerCenter. @NM_Urology.

As May is Bladder Cancer Awareness Month, @Larvol CLIN highlights the top 10 trials from the @AmerUrological (AUA) 2025. Discover more: t.ly/efSba #LARVOL #AUA25 #BladderCancer #CancerResearch #Oncology #CancerData #ClinicalTrials #CancerCare #MIBC #NMIBC |…

May is Bladder Cancer Awareness Month! 🧡 Throughout the month, we’ll be spotlighting recent episodes focused on this common but often overlooked disease. Stay tuned and help spread awareness! @BladderCancerUS @IBCG_BladderCA

The Future is BRIGHT! Excited for Leslie Ballas bladder preservation trial for responders after NAC. Love this trial, and aligns w much of what we do already. @SWOG @NRGonc @mouwlab

Used @VanAllenLab recent AI review to prep for Vogelzang Symposium @SWOG @FaltasLab @Cancer_Cell

Please join us in congratulating Ali Shilatifard, PhD (@ShilatifardLab), the Robert Francis Furchgott Professor and chair of Biochemistry and Molecular Genetics, who has been elected to @theNASciences. Read the story: tinyurl.com/3kdn5f43

Celebrating the election of our amazing Chair of Biochemistry & Molecular Genetics Ali Shilatifard ⁦@ShilatifardLab⁩ to the ⁦@theNASciences⁩. Such a great honor for ⁦@NorthwesternU and ⁦@NUFeinbergMed⁩. Congratulations Ali!